Viridian Therapeutics Inc
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develo… Read more
Viridian Therapeutics Inc (VRDN) - Total Assets
Latest total assets as of December 2025: $899.42 Million USD
Based on the latest financial reports, Viridian Therapeutics Inc (VRDN) holds total assets worth $899.42 Million USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Viridian Therapeutics Inc - Total Assets Trend (2012–2025)
This chart illustrates how Viridian Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Viridian Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Viridian Therapeutics Inc's total assets of $899.42 Million consist of 99.4% current assets and 0.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 23.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Viridian Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Viridian Therapeutics Inc's current assets represent 99.4% of total assets in 2025, an increase from 59.8% in 2012.
- Cash Position: Cash and equivalents constituted 23.6% of total assets in 2025, up from 4.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Viridian Therapeutics Inc Competitors by Total Assets
Key competitors of Viridian Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Viridian Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Viridian Therapeutics Inc generates 0.08x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Viridian Therapeutics Inc is currently not profitable relative to its asset base.
Viridian Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.65 | 15.43 | 7.39 |
| Quick Ratio | 12.65 | 15.43 | 7.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $823.54 Million | $ 690.59 Million | $ 105.10 Million |
Viridian Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Viridian Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.06 |
| Latest Market Cap to Assets Ratio | 3.25 |
| Asset Growth Rate (YoY) | 21.1% |
| Total Assets | $899.42 Million |
| Market Capitalization | $2.92 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Viridian Therapeutics Inc's assets at a significant premium ( 3.25x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Viridian Therapeutics Inc's assets grew by 21.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Viridian Therapeutics Inc (2012–2025)
The table below shows the annual total assets of Viridian Therapeutics Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $899.42 Million | +21.15% |
| 2024-12-31 | $742.40 Million | +51.38% |
| 2023-12-31 | $490.42 Million | +12.72% |
| 2022-12-31 | $435.09 Million | +113.58% |
| 2021-12-31 | $203.71 Million | +55.20% |
| 2020-12-31 | $131.25 Million | +333.73% |
| 2019-12-31 | $30.26 Million | -54.25% |
| 2018-12-31 | $66.15 Million | +26.04% |
| 2017-12-31 | $52.48 Million | +1132.24% |
| 2016-12-31 | $4.26 Million | -66.99% |
| 2015-12-31 | $12.90 Million | +59.50% |
| 2014-12-31 | $8.09 Million | +120.25% |
| 2013-12-31 | $3.67 Million | +32.08% |
| 2012-12-31 | $2.78 Million | -- |